Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach

被引:10
作者
Ascoli, Valeria [1 ]
Minelli, Giada [2 ]
Cozzi, Ilaria [3 ]
Romeo, Elisa [3 ]
Scalzo, Caterina Carnovale [3 ]
Ancona, Laura [3 ]
Forastiere, Francesco [3 ]
机构
[1] Sapienza Univ, Dept Radiol Oncol & Anatomopathol Sci, Viale Regina Elena 324, I-00161 Rome, Italy
[2] Ist Super Sanita, Italys Inst Publ Hlth, Unit Stat, Viale Regina Elena 299, I-00161 Rome, Italy
[3] Lazio Reg Hlth Serv, Dept Epidemiol, Via Cristoforo Colombo 112, I-00147 Rome, Italy
关键词
Malignant pleural mesothelioma; Pathology reporting; Immunohistochemistry; Diagnosis; Cancer registry; EPITHELIOID MESOTHELIOMA; MINIMAL PANEL; IMMUNOHISTOCHEMISTRY; GUIDELINES; CANCER; ANTIBODIES; RECOMMENDATIONS; ADENOCARCINOMA; CONTROVERSIES; EXPRESSION;
D O I
10.1016/j.prp.2016.07.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Accurate pathologic diagnosis and reporting in malignant pleural mesothelioma are essential for clinical care, and cancer registration. Practical guidelines for pathologists are provided in publications and textbooks but it is unclear how these recommendations are applied in routine practice. We investigated the characteristics of pathology reports, and the extent to which they meet guideline standards. We reviewed 819 pathology reports relating to a first diagnosis of malignant pleural mesothelioma. Data sources were a regional section of the Italian network of the Mesothelioma Registry (2001-2014) and a pathology archive (1990-2000). We evaluated tumor characteristics, the diagnosis field including terminology and immunohistochemistry (IHC) workup, and report completeness (the proportion of items recorded). We investigated also two IHC panels identified by the most used markers in current practical guidelines, one best suited for epithelioid mesotheliomas (combinations of at least 2 positive and at least 2 negative mesothelioma markers) and the other best suited for sarcomatoid mesotheliomas (positive mesothelioma markers plus cytokeratins). Reports (753 histology, 66 cytology, IHC-confirmed 86%) were 74% complete and always narrative. Missing data were related to clinical history (76%), tumor laterality (61%), specimen size (38%), and histological subtype (23%). The proportion of cases with IHC was higher for epithelioid (90%) than sarcomatoid mesothelioma (87%). Compliance to IHC recommendations was higher for epithelioid (59%) than sarcomatoid mesothelioma (11%). The mean number of stains was significantly higher for sarcomatoid than epithelioid mesothelioma (p<0.000; Kruskal-Wallis test). Our findings show that although guidelines are designed to improve actual reporting practices, there is ample room for improvement in their application to standardize the diagnosis of mesothelioma. Synoptic pathology reporting needs to be implemented to better utilize pathology information. (C) 2016 Elsevier GmbH. All rights reserved.
引用
收藏
页码:886 / 892
页数:7
相关论文
共 50 条
  • [41] Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma
    Zhang, Weiquan
    Wu, Xinshu
    Wu, Licun
    Zhang, Weidong
    Zhao, Xiaogang
    ANNALS OF TRANSLATIONAL MEDICINE, 2015, 3 (13)
  • [42] Surgical Therapy for Malignant Pleural Mesothelioma in Mexican Population
    Marmolejo Torres, M. E.
    Baez Saldana, R.
    Berrios Mejia, J. A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1180 - S1180
  • [43] Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma
    Gee, Gretchen V.
    Koestler, Devin C.
    Christensen, Brock C.
    Sugarbaker, David J.
    Ugolini, Donatella
    Ivaldi, Giovanni P.
    Resnick, Murray B.
    Houseman, E. Andres
    Kelsey, Karl T.
    Marsit, Carmen J.
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) : 2859 - 2869
  • [44] h-caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type
    Comin, CE
    Dini, S
    Novelli, L
    Santi, R
    Asirelli, G
    Messerini, L
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (04) : 463 - 469
  • [45] Survival of peritoneal malignant mesothelioma in Italy: A population-based study
    Mirabelli, Dario
    Roberti, Sara
    Gangemi, Manuela
    Rosato, Rosalba
    Ricceri, Fulvio
    Merler, Enzo
    Gennaro, Valerio
    Mangone, Lucia
    Gorini, Giuseppe
    Pascucci, Cristiana
    Cavone, Domenica
    Nicita, Carmela
    Barbieri, Pietro Gino
    Marinaccio, Alessandro
    Magnani, Corrado
    Montanaro, Fabio
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (01) : 194 - 200
  • [46] Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology
    Nakai, Toshiyuki
    Matsumoto, Yuji
    Sasada, Shinji
    Tanaka, Midori
    Tsuchida, Takaaki
    Ohe, Yuichiro
    Motoi, Noriko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (06) : 559 - 566
  • [47] Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma
    Yang, Yi-Wei
    Marrufo, Angelica
    Chase, Jillian
    Woodard, Gavitt A.
    Jablons, David M.
    Lemjabbar-Alaoui, Hassan
    EXPERIMENTAL LUNG RESEARCH, 2021, 47 (01) : 9 - 25
  • [48] 'It's all bad news': the first 3 months following a diagnosis of malignant pleural mesothelioma
    Arber, Anne
    Spencer, Lesley
    PSYCHO-ONCOLOGY, 2013, 22 (07) : 1528 - 1533
  • [49] On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016)
    Barbieri, Pietro Gino
    Mirabelli, Dario
    Magnani, Corrado
    Brollo, Alessandro
    TUMORI JOURNAL, 2019, 105 (04): : 304 - 311
  • [50] THE ROLE OF PET/CT IN STAGING AND SURGICAL APPROACH FOR MALIGNANT PLEURAL MESOTHELIOMA
    Lequaglie, Cosimo
    Giudice, Gabriella
    Rolfo, Christian
    Marasco, Daniela R.
    Della Morte, Aniello
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S486 - S486